#China #Hong Kong #AI Innovations #Fangzhou Inc. #Internet Healthcare

Overview of Fangzhou Inc.'s 2024 Performance

Fangzhou Inc., a key player in the Internet healthcare domain, revealed its financial results for the fiscal year 2024. The company reported total revenue of RMB 2.7 billion, marking an 11.2% increase compared to the previous year. Even more impressive is the 139% surge in adjusted net profit, which amounted to RMB 17.2 million. These significant gains can be attributed to the company's robust technological advancements and enhanced operational efficiencies, particularly through AI-driven initiatives.

Leadership Statement

Dr. Xie Fangmin, the founder and CEO, shared insights on the company's trajectory, emphasizing that 2024 symbolizes a pivotal advancement for the firm. He stated that their commitment to the H2H (Human to Human) model and the mission to provide cutting-edge Chronic Disease Management (CDM) services are integral to their strategic plan. The company aims to align with national healthcare policies, employing AI to forge a dynamic, patient-centric ecosystem pivotal for the advancement of China's online healthcare sector.

Emphasis on AI-Driven Innovation

Fangzhou's growth strategy centers around its motto of 'AI Powered, Innovation-Driven Growth'. The firm has substantially boosted its research and development efforts, focusing on AI technologies such as large language models and big data analytics. Such advancements have been fundamental in enhancing chronic disease management across their platform. As of December 31, 2024, Fangzhou's Jianke platform boasted 49.2 million registered users, with a remarkable 20% year-on-year increase in average monthly active users, reaching 10.1 million. Furthermore, patient engagement remains high, as seen in the 84.7% repeat purchase rate among paying users.

Expansion of Healthcare Services

Determined to improve accessibility for chronic disease patients, Fangzhou has also introduced an online medical insurance payment system via its platform. This initiative aims to alleviate the financial burden faced by these patients, ultimately enhancing their healthcare experience.

Growth of Physician Network

In 2024, Fangzhou made significant strides in expanding its physician network, crucial for strengthening its service capabilities. The number of registered physicians on the platform reached 223,000, comprising doctors predominantly from Class III hospitals or holding associate chief physician titles or higher. To bolster physician engagement, the company launched new technologies, including a Sales Force Automation (SFA) system and Social Customer Relationship Management (SCRM), targeting underserved regions and fostering timely response to physician needs.

Financial Segments and Innovations

Key business segments registered steady growth. Notably, Online Retail Pharmacy Services saw a revenue increase of 8.3% to RMB 1.405 billion, while allowing patients access to approximately 215,000 drug SKUs on the platform. Furthermore, Customized Content Marketing Solutions achieved a revenue growth of 20.7%, signaling robust demand for tailored healthcare solutions.

Supply Chain Advancements

Fangzhou's supply chain enhancements are pivotal, with collaborations extending to over 1,500 suppliers and more than 900 pharmaceutical companies. This robust network not only ensures a diverse range of pharmaceuticals but also fortifies their market position in the healthcare sector.

Future Outlook

Looking ahead, the company’s strategic priorities for 2025 include further enhancing AI capabilities, optimizing physician engagement, advancing supply chain efficiencies, and investing in talent development. By driving innovation and market leadership in online Chronic Disease Management, Fangzhou continues its mission of improving healthcare access and quality for chronic disease patients in China.

About Fangzhou Inc.

Fangzhou Inc. (06086.HK) stands as China's leading online chronic disease management platform. As of year-end 2024, with 49.2 million registered users and 223,000 registered doctors, the company is committed to providing personalized medical care and precision medicine for the rising number of chronic disease patients in the region.

For further insights and details about Fangzhou's initiatives and services, visit their official investor page.